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Summary 
An increasing number of surgical strabismus patients are taking oral anticoagulant and 
antiplatelet agents, with more diverse mechanisms of action than those used in the past. The 
decision as to whether to continue these drugs throughout the perioperative period is difficult and 
must be based on the balance between hemorrhagic and thrombotic risk. To help guide 
strabismus surgeons with clinical management in these cases, we review potential hemorrhagic 
complications of strabismus surgery and examine the use of anticoagulant and antiplatelet drugs 
during the perioperative period. Surgical strategies that might help minimize intraoperative 
hemorrhage in patients on anticoagulant therapy are also discussed. 
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Ophthalmologists are increasingly likely to encounter patients on anticoagulation and antiplatelet 
therapy (ACAPT). The frequency of adult strabismus surgery has increased by up to 24% over 
the past 15 years, with a peak incidence in the 8th decade of life.1,2 This adult population has 
shown a steady rise in the use of anticoagulation therapy, with a 38% increase in the use of oral 
anticoagulation between 2009 and 2014 in the United States.3 Approximately half of these 
patients are on the newer non-vitamin K oral anticoagulants, such as dabigatran and rivaroxaban, 
which were introduced in 2010. Similarly, there was a 57% increase in the regular use of aspirin 
between 2005 and 2010.4 
Therefore, surgeons can expect an increasing number of strabismus patients to be on 
ACAPT, underscoring the need to understand how these medications affect surgical planning. 
We review the hemorrhagic complications of strabismus surgery and provide an update on 
existing antiplatelet and anticoagulant agents to lay groundwork for managing strabismus 
patients on ACAPT. 
Potential Hemorrhagic Complications of Strabismus Surgery 
Most published guidelines examining the perioperative management of anticoagulation 
categorize ocular surgery as low hemorrhagic risk, but they rarely separate strabismus surgeries 
from other ophthalmic procedures. While the risk of vision-threatening hemorrhage in strabismus 
surgery is extremely low, hemorrhagic complications can cause significant morbidity. Thus, 
careful surgical planning is required to prevent complications. 
One of the most devastating complications of strabismus surgery is retrobulbar 
hemorrhage. There are case reports of retrobulbar hematomas occurring in anticoagulated 
patients undergoing regional anesthesia, including peribulbar, retrobulbar, and sub-Tenon’s 
blocks.5 Large-scale studies are divided on whether there is an increased risk of visually 
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significant hematomas in these patients, probably because of the rarity of this complication.6-8 
Although the risk is low, the consequences are vision threatening, and surgeons should consider 
alternatives to regional anesthesia in anticoagulated patients.  
Retrobulbar hemorrhage associated with strabismus surgery without regional anesthesia 
has also been reported. Carden and colleagues9 published a case of bilateral retrobulbar 
hemorrhage during routine bilateral strabismus surgery under general anesthesia; the patient was 
later discovered to be using high-dose garlic supplements, which have antiplatelet activity and 
may have contributed to the hemorrhage. Arès and Superstein10 reported a case of spontaneous 
retrobulbar hemorrhage 2 days after strabismus surgery, presenting as an infected hematoma and 
orbital cellulitis. Todd and colleagues11 described a retrobulbar hemorrhage 36 hours after 
surgery triggered by coughing and straining. Surgeons should be vigilant for any signs of orbital 
compartment syndrome and be prepared to perform a lateral canthotomy and cantholysis. 
Bleeding complications not only threaten vision but may also cause muscle slippage requiring 
surgical reexploration and repair.12 
Other hemorrhagic complications can affect patient comfort and perception of surgical 
outcomes. Eyelid hemorrhages, which can occur independently of regional blocks, can cause 
discomfort and patient distress due to appearance. These hemorrhages are more common after 
surgery on the inferior oblique muscle. In addition to the disturbing appearance, subconjunctival 
hemorrhages can also cause corneal dellen, placing the patient at risk of corneal perforation if not 
appropriately managed. 
The effect of anticoagulation on surgical outcomes has been studied in cataract, 
vitreoretinal, oculoplastics, and glaucoma surgeries,13-16 but the effect on strabismus surgery has 
been little studied. Kemp and colleagues17 published a case series of 3 patients successfully 
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undergoing strabismus surgery while taking warfarin, without complications. However, Coats 
and Olitsky18 reported that patients on anticoagulation are more likely to require cautery for 
hemostasis during strabismus surgery (14.8% vs 1.2%), suggesting that these patients have more 
intraoperative bleeding. Thus, an understanding of available antiplatelet and anticoagulant drugs 
is important in order to strike a safe balance between hemorrhagic and thrombotic risks. 
Antiplatelet Agents 
Aspirin (Acetylsalicylic acid, ASA) 
ASA is widely used for the primary and secondary prevention of cardiovascular disease and has 
been found to decrease all-cause mortality, major cardiovascular events, and colorectal 
cancer.19,20 Zhou and colleagues4 estimates a 57% increase in regular aspirin use in the United 
States between 2005 to 2010. In addition, Stuntz and Bernstein21 found that 30% of adults over 
the age of 40 take aspirin on a regular basis. 
Aspirin suppresses the production of prostaglandins and thromboxane by irreversibly 
inhibiting cyclooxygenase. The loss of thromboxane in platelets leads to decreased affinity for 
platelet aggregation for the lifetime of the platelet. The antiplatelet effect, which is responsible 
for the cardiovascular benefit of regular aspirin use, also makes intraoperative hemostasis more 
challenging.  
Because aspirin functions as a nonreversible inhibitor, the duration of the antiplatelet 
effect depends on the rate of platelet turnover. Platelets exposed to aspirin will be inhibited, but 
platelets made after aspirin dosing will not be affected. It has been suggested that patients 
discontinue aspirin 3 days prior to planned surgery, because hemostasis is normalized if 20% of 
platelets have normal cyclooxygenase activity, and 12% of circulating platelets are replaced 
every 24 hours.22,23 One study in healthy volunteers showed complete normalization of platelet 
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function and bleeding times by 6 days after aspirin cessation in 100% of study subjects, 
independent of dosing.24 Thus, if platelet normalization is required for surgery, stopping aspirin 
at least 5-7 days prior to surgery is recommended.  
Patients with recent coronary artery angioplasty or stent placement are at particularly 
high risk of thrombotic complications and myocardial infarction during the perioperative period 
because of increased risk of thrombosis and discontinuation of antiplatelet medications.25,26 
Current guidelines suggest delaying elective noncardiac surgery for 14 days after coronary artery 
balloon angioplasty, 30 days after bare metal stent implantation, and 1 year after drug-eluting 
stent implantation if antiplatelet agents need to be discontinued for the procedure.27 Some have 
suggested that with the newer generation of drug-eluting stents, delaying elective surgery for 180 
days is sufficient to lower the risk to the baseline.27 
The benefit of aspirin as primary prevention in nonstented patients is uncertain, and 
guidelines suggest that initiation or continuation of aspirin is not beneficial in patients 
undergoing elective noncardiac noncarotid surgery.28 
Non-steroidal Anti-inflammatory Drugs (NSAIDs) 
Commonly used for analgesia, NSAIDs function similarly to aspirin via cyclooxygenase 
inhibition. However, in contrast to aspirin, their inhibitory action is reversible, which leads to a 
decreased duration of antiplatelet effect. Normalization of platelet function depends on the half-
life of the particular NSAID used: ibuprofen has a half-life of approximately 2 hours, whereas 
naproxen has a half-life of 17 hours.  
Gobble and colleagues29 examined the use of ketorolac postoperatively in a range of 
nonophthalmic surgeries, and found no evidence to suggest an increase in postoperative 
bleeding. In uncomplicated cases, ketorolac and other NSAIDS may be used safely for 
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postoperative pain, but in complex cases, or those with several risk factors, other analgesic 
agents should be considered. Topical NSAIDs may be effective as a postsurgical analgesic and 
can be used as an alternative to systemic administration.30 
ADP/P2Y12 Inhibitors 
As a class, adenosine diphosphate (ADP) receptor inhibitors, including clopidogrel, prasugrel, 
ticlodipine, and ticagrelor, are most commonly used in the acute setting for myocardial 
infarction. These drugs can also be used in patients who cannot tolerate aspirin, since they have 
similar prophylactic efficacy for cardiovascular protection. In patients who have undergone 
coronary stenting, ADP inhibitors are frequently used in combination with aspirin for a dual 
antiplatelet effect to minimize the risk of stent thrombosis.  
The antiplatelet effect of these drugs is mediated by the inhibition of P2Y12 subtype of 
ADP receptors on platelet cell membranes, which is critical for platelet aggregation. Like aspirin, 
clopidogrel, prasugrel, and ticlodipine have irreversible inhibition; therefore, restoration of 
normal platelet function in these patients depends on the rate of platelet turnover. Ticagrelor 
inhibition is reversible, with a half-life of about 8 hours, and, along with prasugrel, it is thought 
to have greater clinical efficacy than clopidogrel. If normal platelet function is desired for 
surgery, recent guidelines suggest a 5-day abstinence period for clopidogrel, ticlodipine, and 
ticagrelor, and 7 days for prasugrel.31 
Anticoagulant Agents 
Heparin 
Heparin, a naturally occurring anticoagulant that binds to and activates antithrombin III, which 
then inactivates thrombin and factor Xa in the coagulation cascade, is available as unfractionated 
heparin (UNF) and low-molecular weight heparins (LMWH). It is frequently used to treat 
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myocardial infarction and is also used in the management of atrial fibrillation, pulmonary 
emboli, and venous thromboembolisms. Heparin is not absorbed orally and must be administered 
parenterally, either subcutaneously or intravenously. 
Due to the short half-life of heparin, normalization of hemostatic ability occurs within 
hours of last administration, usually 1-2 hours for UNF and within 5-6 hours for LMWH. 
Protamine sulfate may be used for more rapid reversal of UNF heparin action. 
Warfarin 
Warfarin inhibits vitamin-K dependent synthesis of clotting factors II, VII, IX, X and proteins C 
and S.32 In medical use since 1954, it is frequently used for the treatment of pulmonary emboli 
and deep venous thrombosis and is also used for thromboembolic prophylaxis in atrial 
fibrillation and prosthetic heart valve implantation.  
Warfarin dosing is patient dependent and requires laboratory monitoring to titrate the 
correct dosage. Prothrombin time, and the derived international normalized ratio (INR), are used 
to assess a patient’s coagulative function. The target INR for most patients lies between 2.0 and 
3.0, although prosthetic heart valve patients require a higher anticoagulation goal of 2.5-3.5. 
Warfarin’s half-life is approximately 36-42 hours; thus, normalization of INR may take 5 
days. However, this depends on initial INR and the patient’s ability to synthesize clotting factors. 
The American College of Chest Physicians recommends a target INR of <1.5 for most surgical 
procedures, although the recommendation does not specifically discuss strabismus surgery.33 
Administration of vitamin K accelerates normalization of hemostatic ability by augmenting 
natural synthesis of clotting factors. More rapid reversal of warfarin activity, as may be required 
in massive hemorrhage, requires the transfusion of fresh frozen plasma, which contains the 
downregulated clotting factors. 
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Because of the amount of time needed to reach the target INR both when initiating and 
stopping warfarin therapy, there is concern for recurrent thromboembolism in high-risk patients. 
In addition, initiating warfarin therapy leads to a temporary state of hypercoagulability, which 
lasts approximately 3 days because of the more rapid downregulation of anticoagulant proteins C 
and S.34 To mitigate this risk, patients may require heparin bridging in the perioperative 
transitional period. 
Patients being discontinued from warfarin are stratified based on their risk of 
thromboembolism. It is recommended that patients at low risk for thromboembolism not use a 
heparin bridge.33 For patients at high risk for thromboembolism, warfarin is discontinued 5 days 
before the surgical procedure and heparin is started to prevent thrombotic complications of 
inadequate anticoagulation. Historically this was accomplished at the hospital once the INR is 
below 2.0 for initiation of intravenous UNH. Heparin was administered until 4-6 hours before the 
surgical procedure. Following the procedure, with hemostasis and low risk of bleeding, heparin 
could be restarted. Generally, it was recommended that warfarin be restarted12-24 hours after 
hemostasis, although, because there is no reversal agent for warfarin, some chose to delay 
restarting warfarin in select cases. The patient remained in the hospital until the INR is >2.0, at 
which point the heparin can be discontinued.  
The development of LMWH has allowed outpatient management of a heparin bridge.33 It 
is recommended that LMWH be stopped 24 hours before the procedure. Other important, but 
often overlooked, aspects of perioperative heparin bridging include providing a patient calendar 
for stopping and starting anticoagulation medications, patient education for the administration of 
LMWH, rechecking INR levels before surgery to ensure a return to baseline, and discussion of 
risks/benefits of heparin bridging. 
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Direct Thrombin Inhibitors 
This drug class disrupts the anticoagulation cascade by way of factor II (thrombin) inhibition and 
includes dabigatran, bivalirudin, argatroban, and desirudin. Of these, only dabigatran is available 
in an oral form and is thus the most likely to be encountered by strabismus surgeons. Dabigatran, 
introduced in 2010, has evolving clinical indications and the benefit of more rapid onset and no 
need for therapeutic monitoring, while having a similar safety profile as warfarin.35,36 
Like other anticoagulants, dabigatran is most frequently used in the management of 
venous thromboembolism, atrial fibrillation, and, less commonly, for acute coronary syndrome. 
Because it is eliminated by the kidneys, the duration of anticoagulation activity depends on the 
individual’s renal function. If there is low hemorrhagic risk in a patient with normal creatinine 
clearance, dabigatran can be discontinued 24-48 hours prior to surgery.37 In patients with 
impaired renal clearance (CrCl <50), or for patients with high hemorrhagic risk, it should be 
discontinued 3-5 days prior to surgery.  
Rapid reversal in an emergent or life-threatening setting can be accomplished by 
administration of idarucizumab. Dabigatran reaches peak anticoagulant effect within 2-3 hours of 
administration, so there is no need for heparin bridging when resuming therapy. This drug can be 
restarted within 24 hours for procedures with low hemorrhagic risk and 48-72 hours for high-risk 
procedures. 
Direct Factor Xa Inhibitors 
The direct factor Xa inhibitors, which first became available in 2011, include rivaroxaban, 
apixaban, and edoxaban and are approved for use for atrial fibrillation and venous 
thromboembolism. Along with dabigatran, they are often referred to under the umbrella term 
“novel oral anticoagulants” or “non-vitamin K anticoagulants” (NOACs). Like dabigatran, this 
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class also benefits from an onset of action within 1-4 hours and no need for laboratory 
monitoring. If preoperative confirmation of residual anticoagulant affect is desired, factor Xa 
levels can be drawn. 
These medications are cleared through the kidneys, with half-lives typically ranging 
between 5-12 hours. If planning to discontinue anticoagulation in patients with normal creatinine 
clearance and low thromboembolic risk, rivaroxaban and apixaban can be discontinued 24-48 
hours preoperatively, and edoxaban can be discontinued 72 hours prior. These medications 
should be stopped earlier in patients with decreased creatinine clearance, depending on the 
degree of renal impairment. The bleeding risk profile is favorable for these medications 
compared to warfarin.38 For rapid reversal of anticoagulation, andexanet alfa is a recombinant 
protein that has been recently approved for use by the Food and Drug Administration.39 
Herbal Supplements 
St John’s wort, ginkgo biloba, garlic, and ginseng have varying levels of antiplatelet and 
anticoagulant effects, which are most notable in patients already on antithrombotic medications. 
Carden and colleagues9 document bilateral retrobulbar hemorrhage during routine bilateral 
lateral rectus recession in a patient taking large quantities of garlic extract. Fong and colleagues40 
reported a case of retrobulbar hemorrhage after retrobulbar anesthesia in a patient on gingko 
biloba. In both cases, the patients did not inform their surgeons about their herbal 
supplementation, which demonstrates how easily these alternative medicines may be overlooked 
by both patients and providers. In practice, it is impossible to make concrete recommendations 
on whether to postpone surgery when patients take these supplements. Cases should be evaluated 
on risk and individual histories. 
Managing Anticoagulants and Antiplatelet Agents in the Perioperative Period 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The decision on whether and for how long to discontinue antithrombotic agents depends on 
balancing hemorrhagic and thrombotic risk. This assessment should be made in coordination 
with the patient’s primary care provider or cardiologist to best determine the degree of risk 
associated with anticoagulation cessation. Once the risk has been determined, a decision can be 
made about how best to manage the patient’s antiplatelet or anticoagulant drugs during the 
perioperative period (Figure 1). 
Determining Hemorrhagic Risk 
The patient’s medical issues should be carefully considered in the assessment of perioperative 
hemorrhagic risk. Several coexisting diseases can exacerbate the problem. Uncontrolled 
hypertension can make intraoperative hemorrhage difficult to control. Patients with impaired 
renal and hepatic function may have an inherent coagulopathy, and impaired anticoagulant 
clearance may require earlier preoperative medication discontinuation or monitoring of 
coagulability prior to surgery (Table 1). Chronic alcohol use also impairs coagulation by 
affecting platelet function and factor synthesis. Obtaining an accurate history of personal and 
family of bleeding will aid in uncovering conditions such as hemophilia, von Willenbrand factor 
deficiency, or Glanzmann’s thrombasthenia, which can significantly increase hemorrhagic risk.  
Intraoperative factors can also affect the degree of surgical hemorrhage. The risk increases with 
more complex procedures or with reoperations because of prolonged operative time and 
increased surgical disruption of underlying anatomy. The type of anesthesia can also affect 
hemorrhagic risk. While regional anesthesia can result in retrobulbar hemorrhage, general 
anesthesia can lead to coughing and bucking during extubation and bleeding at the surgical site.  
Determining Thrombotic Risk 
Both the European Society of Cardiology and the American Heart Association/American College 
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of Cardiology/Heart Rhythm Society recommend using the CHA2DS2-VASC score to stratify 
atrial fibrillation patients as high, medium, or low risk for thromboembolism.41,42,27 According to 
these guidelines, patients with prosthetic mitral valves, recent strokes or transient ischemic 
attacks, recent thromboembolism, or a history of thrombophilia have a >10% annual risk for 
thromboembolic events. Interruption of anticoagulation for strabismus surgery should be 
carefully assessed for these patients. If in discussion with the patients’ physicians, cessation of 
therapy is agreed upon, then heparin bridging will be required to minimize perioperative risk. In 
contrast, low-risk patients do not need bridging therapy (Table 2).  
Patients on antiplatelet therapy can be similarly stratified on risk. Aspirin can be safely 
discontinued in patients without a history of myocardial infarction or stroke. In contrast, a trial 
by Oscarsson and colleagues43 found that high-risk patients benefit from continuation of 
perioperative antiplatelet therapy. This study demonstrated that continuation of aspirin in the 
perioperative period in patients with a history of ischemic heart disease, congestive heart failure, 
renal impairment, stroke or transient ischemic attack, or insulin-dependent diabetes significantly 
decreased the rate of cardiovascular events (1.8% vs 9.0% [P = 0.02]). 
For patients with recent coronary stenting, the risk of stent thrombosis appears to be 
greatest within the first 6 weeks of placement for bare-metal stents and within the first 6 months 
for drug-eluting stents (ACCP guidelines). Since dual antiplatelet therapy should be continued 
without interruption during this time, ophthalmologists should consider delaying strabismus 
surgery until the patient is outside this window. 
Analgesia Considerations 
Strabismus surgery requires minimal postoperative analgesia. Local analgesia in combination 
with acetaminophen and occasionally low-dose opioids is usually sufficient. Ketorolac, and 
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intravenous NSAIDs, can impair platelet function and may increase postoperative bleeding. In 
patients who are at high risk for bleeding, ketorolac should not be used in the peri-operative 
period. Since strabismus surgery is inherently nauseating, opioids should be used sparingly. 
Intravenous acetaminophen is a good choice for analgesia in patients who are unable to tolerate 
oral medications, and in whom ketorolac is contraindicated. 
Local Control of Hemostasis During Surgery 
Agents with alpha-agonist activity, such as epinephrine and oxymetazoline, can be applied 
topically to induce vasoconstriction and decrease intraoperative hemorrhage. These agents can be 
placed directly onto the eye after surgical field preparation, so the effect of vasoconstriction is 
working as the surgeon makes the first incision. When using epinephrine as the vasoconstricting 
agent, a concentration of 1:10,000 (100 mcg/ml) should be used for routine cases and of 1:1,000 
(1000 mcg/ml) for cases with greater hemostatic concern. Although the risk of cardiovascular 
effects is minimal with topically applied epinephrine, tachycardia and hypertension can occur. In 
patients in whom these effects would have negative consequences, discussion with the anesthesia 
provider prior to administration will be helpful. 
Careful surgical technique can help minimize surgical bleeding even in the setting of 
anticoagulant and antiplatelet therapy. Identification of conjunctival and ciliary vessels is crucial, 
so the surgeon can avoid or gently cauterize these vessels. Cautery may be used early in the 
surgery during muscle isolation and suture placement to avoid bleeding. Cautery prior to 
dissection of connective tissues with small vessels may also be helpful, and oxymetazoline-
soaked cotton-tip applicators can be used for blunt dissection. Suturing the muscle deep to the 
vessels can help to avoid inadvertent nicking of the vessels.  
Conclusions 
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The landscape of anticoagulant and antiplatelet therapies is rapidly evolving, with an increasing 
arsenal of drugs becoming available, accompanied by complex indications for use. As more 
surgical patients are taking these medications, it is important that the strabismus surgeon 
understand how to approach clinical care in these cases. Surgical hemorrhagic and thrombotic 
risks must be carefully balanced, and the timing of antithrombotic cessation should be 
individualized with the assistance of the patient’s primary care physician, cardiologist, or 
neurologist. 
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Legends 
FIG 1. Suggested preoperative algorithm for optimizing hemorrhagic risk of the strabismus 
surgery process. 
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Table 1. Commonly used antiplatelet and anticoagulant drugs, half-lives, and route of drug clearance 
 
Drug Trade Name Mechanism Half-life Clearance 
Aspirin — Cyclooxygenase inhibitor 2-3 hours Renal 
Clopidogrel Plavix ADP/P2Y12 inhibitor 7-8 hours Hepatic 
Warfarin Coumadin Vitamin K antagonist 20-60 hours Renal 
Enoxaparin Lovenox Low molecular weight heparin 4.5 hours Renal 
Dabigatran Pradaxa Thrombin inhibitor 14-17 hours Renal 
Rivaroxaban Xarelto Factor Xa inhibitor 8-9 hours Renal, fecal 
Apixaban Eliquis Factor Xa inhibitor 7-8 hours Renal, fecal 
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Table 2. Risk stratification for perioperative thromboembolism (Douketis and colleagues33) 
 
Risk Mechanical heart valve Atrial fibrillation Venous thromboembolism 
High • Any mitral valve prosthesis • CHADS2 score of 5 or 6 • VTE within 3 months 
• Caged-ball or tilting disc aortic 
valve prosthesis 
• Rheumatic valvular heart 
disease 
• Severe thrombophilia (eg 
protein C/S deficiency, 
antiphospholipid antibodies) 
• Stroke or TIA within 6 months • Stroke or TIA within 3 
months 
 
Moderate • Bileaflet aortic valve prosthesis 
and any major stroke risk 
factors 
• CHADS2 score of 3 or 4 • Recurrent VTE 
• VTE within 3-12 months 
Low • Bileaflet aortic valve prosthesis 
without any major stroke risk 
factors 
• CHADS2 score of 0-2 and 
no recent stroke or TIA 
• Active cancer 
• VTE >12 months, no other 
risks 
CHADS2, congestive heart failure, hypertension, age>75 years, diabetes mellitus, stroke or transient 
ischemic attack; TIA, transient ischemic attack; VTE, venous thromboembolism. 
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